Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of$ 0.93. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.68%. A quarter ago, it was expected that this company would post a loss of$ 0.99 per share when it actually produced a loss of $0.48, delivering a surprise of 51.52%. Over the last four quarters, the company has ...